抗体D5F3及Survivin在非小细胞肺癌患者中的临床应用价值分析

摘要

目的 探讨D5F3及Survivin在非小细胞肺癌患者中的临床应用价值.方法 选取我院2016年1月～2017年6月收治的非小细胞肺癌患者100例,采用免疫组化法进行检测,分析新型抗体D5F3和Survivin抗体在非小细胞肺癌患者中的临床诊断价值.结果 结果 显示D5F3检测(+)符合率为20％,(++)符合率为33.33％,(+++)符合率为87.50％,比较差异有统计学意义(P<0.05).Survivin蛋白表达的阳性率与非小细胞肺癌分化程度、TNM分期、淋巴结转移有关(P<0.05).结论 D5F3检测准确率、敏感性和特异性高,具有重要临床诊断价值;检测Survivin表达情况有助于临床对非小细胞肺癌患者分化程度、临床分期和淋巴结转移的判断.%Objective To investigate the clinical value of D5F3 and Survivin in patients with non-small cell lung cancer. Methods 100 patients with non - small cell lung cancer admitted in our hospital from January 2016 to June 2017 were examined by immunohistochemical method, to analyze the clinical value of D5F3 and Survivin antibody in non - small cell lung cancer (NSCLC). Results The coincidence rate of D5F3 was (20％), (++) was 33.33％, and the coincidence rate was (87.50％), and the difference was statistically significant (P<0.05). The positive rate of Survivin protein expression was correlated with the differentiation degree of non-small cell lung cancer, TNM stage and lymph node metastasis (P<0.05). Conclusion D5F3 has high accuracy, sensitivity and specificity, and has important clinical diagnostic value; The detection of Survivin expression is helpful for clinical differentiation, clinical staging and lymph node metastasis in patients with non-small cell lung cancer.